Study: Cost of developing a new drug tops $1.1 billion


Much has been written about the high cost of drugs. Less has been publicized about how much it costs to get medications to market. Such costs topped $1.1 billion in the 2011-2012 season, according to a new study by Deloitte and Thomson Reuters. That's up $100 million from 2010-2011, based on an examination of a dozen leading firms.

Among the study's findings: The industry has seen a jump in approvals, with 41 between 2011 and 2012, up from 32 between 2010 and 2011. Researchers said the 41 approvals in the 2011-2012 season amounted to $211 billion in projected sales, down from the $309 billion in forecasted sales of the 32 items approved the year before. So while more drugs are getting to market, they are generating smaller returns.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions